Table 2.
Characteristic | No. of Patients (N = 123) | % |
---|---|---|
Median age, years | 61 | |
Sex | ||
Male | 86 | 70 |
Female | 37 | 30 |
Histology | ||
Adenocarcinoma | 56 | 46 |
Squamous | 28 | 23 |
Large cell | 17 | 14 |
Adenocarcinoma with BAC features/BAC | 5 | 4 |
Other | 17 | 14 |
Stage | ||
IIIB | 18 | 15 |
IV | 105 | 85 |
Race | ||
White | 112 | 91 |
Black | 3 | 2 |
Asian | 2 | 1.5 |
Other | 6 | 5 |
Smoking status | ||
Current | 31 | 25 |
Former | 66 | 54 |
Never | 25 | 20 |
Unknown | 1 | < 1 |
V arm, No. of plasma samples | ||
Baseline | 55 | 45 |
Day 8 | 45 | |
Day 22 | 35 | |
Day 43 | 31 | |
CP arm, No. of plasma samples | ||
Baseline | 32 | 26 |
Day 8 | 27 | |
Day 22 | 30 | |
Day 43 | 23 | |
VCP arm, No. of plasma samples | ||
Baseline | 36 | 29 |
Day 8 | 32 | |
Day 22 | 29 | |
Day 43 | 26 |
Abbreviations: BAC, bronchioloalveolar carcinoma; V, vandetanib; CP, carboplatin and paclitaxel; VCP, vandetanib, carboplatin, and paclitaxel.